Rockefeller Scientists Engineer Next-Generation Antibody 100 Times More Potent Than IVIG for Autoimmune Diseases
核心洞察
Researchers at Rockefeller University have developed an engineered antibody that delivers the same therapeutic effect as IVIG at 100 times lower doses in preclinical studies.
The breakthrough builds on 40 years of research into Fc receptors (搜索) and reveals a novel mechanism where FcγRIIB (搜索) and DC-SIGN (搜索) receptors bind together to enhance anti-inflammatory signaling.
The new molecule can be produced synthetically without human plasma, potentially addressing IVIG's supply shortages and enabling treatment of additional autoimmune diseases (搜索) currently limited by dosing constraints.
Scientists at Rockefeller University have engineered a next-generation antibody that could revolutionize treatment for autoimmune diseases (搜索) by delivering the therapeutic benefits of intravenous immunoglobulin (IVIG) therapy at dramatically reduced doses. The breakthrough, published in Science, demonstrates that their engineered molecule achieves the same anti-inflammatory effects as IVIG using 100 times less drug in preclinical mouse models.
The research, led by Jeffrey Ravetch from the Leonard Wagner Laboratory of Molecular Genetics and Immunology, addresses critical limitations of current IVIG therapy, which requires multi-hour, high-volume infusions several times per month and faces frequent supply shortages due to its dependence on donated human plasma.
Novel Receptor Interaction Mechanism Discovered
The key breakthrough came from understanding how three critical components work together to mediate IVIG's anti-inflammatory activity. "We discovered that the type 1 FcγRIIB (搜索) receptor and the type 2 DC-SIGN (搜索) co-receptor are actually binding to each other on the cell surface, and that seems to be important for the anti-inflammatory effect of IgG (搜索)," explains first author Andrew Jones, a research associate in Ravetch's lab.
This novel receptor configuration had not been observed before. The researchers found that when FcγRIIB (搜索) and DC-SIGN (搜索) bind together, they enhance the ability of sialylated IgG (搜索) antibodies to trigger anti-inflammatory signaling cascades. "We discovered that by enhancing the binding of a certain pair of receptors we can significantly lower the dose yet have an equal effect," Jones says.
Dramatic Efficacy Improvements in Preclinical Studies
To test their engineered antibody, researchers used mice expressing human Fc receptors (搜索) and induced arthritis (搜索) by injecting serum from mice with naturally occurring arthritis. Both the new engineered molecule and conventional IVIG reduced joint swelling, but the dosing requirements were strikingly different.
The results showed that 100 times as much IVIG was required to achieve the same therapeutic effect as one dose of the new engineered molecule. "This is a really substantial difference," Ravetch notes, emphasizing the clinical implications of such dramatic potency improvements.
The team also tested their molecule in a mouse model of multiple sclerosis (搜索), where it protected mice from neuroinflammation by preventing cell destruction at the same reduced dose, demonstrating broad applicability across autoimmune conditions.
Building on Decades of Fc Receptor Research
The breakthrough builds on 40 years of research in Ravetch's laboratory focused on Fc receptors (搜索), proteins found on nearly all immune cells that coordinate immune system responses. The work specifically leverages discoveries about immunoglobulin G (IgG (搜索)), which represents 75% of the infection-fighting antibodies in blood and serves as IVIG's key component.
About 25 years ago, Ravetch discovered that a small fraction of serum IgGs in IVIG possessed a sugar modification called sialylation that conferred anti-inflammatory properties. Subsequent studies identified the inhibitory Fc receptor FcγRIIB (搜索) and the lectin DC-SIGN (搜索) as additional required components for triggering anti-inflammatory responses.
These earlier insights led to development of NVG-2089, a molecule 10 times more potent than IVIG that is currently in phase 2 clinical trials through Nuvig (搜索), a biotech company co-founded by Ravetch. The current findings represent a dramatic improvement over that earlier molecule.
Addressing Critical Clinical Needs
IVIG therapy, with origins dating back to the 1950s, is currently FDA-approved for four diseases but widely prescribed off-label to treat more than 80 additional autoimmune conditions because it's often the only available treatment option. However, its limitations have restricted broader clinical application.
"There are many autoimmune diseases (搜索) that currently aren't treated with IVIG because we haven't achieved the correct dosing," Ravetch explains. "With a very high potency product, it's possible to achieve the correct dosage and expand use to more autoimmune diseases."
The new engineered molecule offers additional advantages beyond potency. As a recombinant protein that can be produced in vitro, it eliminates dependence on donated human plasma. "That's an enormous advantage," Ravetch says, addressing one of IVIG's most significant supply chain vulnerabilities.
Clinical Development Pathway
The research team has optioned their engineered molecule to Nuvig (搜索) for further development. "They'll test further to determine if they want to pursue it as a clinical product," Ravetch says. "I hope they do. We want to see it get into patients."
Looking ahead, the laboratory plans to investigate the structure and molecular dynamics of the type 1 and type 2 receptors they've identified. "What we have discovered opens the door to exploring how they might function in different biological pathways," Jones notes, suggesting potential applications beyond autoimmune disease treatment.